title: Effect of captopril on antithrombus function of endothelium.
abstract: The experimental models of cultured porcine aortic endothelial cells (EC) in vitro were established. 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha), thromboxane B2(TXB2)content, plasminogen activator (PA), plasminogen activator inhibitor (PAI) activity in cultured medium and cyclic adenosine monophosphate (cAMP) level in EC were measured with radioimmunoassay (RIA), chromogenic substrates methods, in order to assess the effect and mechanism of captopril (CP) on antithrombus function of EC. The results showed that after administration of CP, the contents of 6-keto-PGF1 alpha and cAMP and PA activity were significantly higher, PAI activity were remarkably lower than those of control group. These effects were dose-dependent. Our finding indicated that CP might act as a prospective drug for antithrombosis through promoting anticoagulation and fibrinolysis function and increasing antithrombus action of EC.
authors.affiliation: Department of Medicine, Tongji Hospital, Tongji Medical University, Wuhan.
authors.forename: Y L
authors.initials: YL
authors.lastname: Xiong
authors.forename: H Y
authors.initials: HY
authors.lastname: Zhao
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D001011:Aorta; D002216:Captopril / Q000494:pharmacology*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D004730:Endothelium, Vascular / Q000166:cytology* / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D013552:Swine; D013929:Thromboxane B2 / Q000378:metabolism
chemical_list: D005343:Fibrinolytic Agents; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D002216:Captopril; D000242:Cyclic AMP